0000000000132675

AUTHOR

Anna Serrano-mollar

showing 2 related works from this author

In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats

2003

1. This study examines the activity of the antioxidant N-acetylcysteine on bleomycin-induced pulmonary fibrosis in rats with emphasis on the early inflammatory phase. 2. Rats receiving N-acetylcysteine (300 mg kg(-1) day(-1), intraperitoneal) had less augmented lung wet weight, and lower levels of proteins, lactate dehydrogenase, neutrophil and macrophage counts in bronchoalveolar lavage fluid and lung myeloperoxidase activity with a betterment of histological score at 3 days postbleomycin. 3. A diminished lung GSH/GSSG ratio and augmented lipid hydroperoxides were observed 3 days postbleomycin. These changes were attenuated by N-acetylcysteine. Alveolar macrophages from bleomycin-exposed r…

PharmacologyPathologymedicine.medical_specialtyNecrosisLungmedicine.diagnostic_testbusiness.industrySuperoxiderespiratory systemmedicine.diseaseBleomycinrespiratory tract diseasesNitric oxideDrug vehiclechemistry.chemical_compoundBronchoalveolar lavageEndocrinologymedicine.anatomical_structurechemistryInternal medicinePulmonary fibrosismedicinemedicine.symptombusinessBritish Journal of Pharmacology
researchProduct

Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats

2003

Oxidative stress is involved in the pathogenesis of pulmonary fibrosis, therefore antioxidants may be of therapeutic value. Clinical work indicates that N ‐acetylcysteine (NAC) may be beneficial in this disease. The activity of this antioxidant was examined on bleomycin-induced lung damage, mucus secretory cells hyperplasia and mucin Muc5ac gene expression in rats. NAC (3 mmol·kg−1·day−1) or saline was given orally to Sprague-Dawley rats for 1 week prior to a single intratracheal instillation of bleomycin (2.5 U·kg−1) and for 14 days postinstillation. NAC decreased collagen deposition in bleomycin-exposed rats (hydroxyproline content was 4,257±323 and 3,200±192 µg·lung−1 in vehicle- and NAC…

MalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyPulmonary FibrosisAdministration OralGene ExpressionMucin 5ACPharmacologyBleomycinmedicine.disease_causeRats Sprague-DawleyAcetylcysteineBleomycinHydroxyprolinechemistry.chemical_compoundAdministration InhalationPulmonary fibrosismedicineAnimalsLungAntibiotics AntineoplasticHyperplasiabusiness.industryMucinMucinsFree Radical Scavengersrespiratory systemmedicine.diseaseMucusAcetylcysteineRatsrespiratory tract diseasesOxidative StresschemistryModels AnimalRespiratory epitheliumbusinessOxidative stressmedicine.drugEuropean Respiratory Journal
researchProduct